Is the COVID-19 pandemic associated with a decrease in the number of cancer screening tests globally?
In this systematic review and meta-analysis of 39 publications, the screening types analyzed were associated with a significant overall decrease (−46.7%, −44.9%, and −51.8% for breast, colorectal, and cervical cancer screening, respectively) from January to October 2020. This decrease showed a U-shaped trend with a negative peak in April 2020 (−74.3% for mammography and −69.3% for colonoscopy and fecal occult blood test or fecal immunochemical test) and in March 2020 for Papanicolaou test or human papillomavirus test (−78.8%).
COVID-19 pandemic measures were associated with widely reduced cancer screening services, which was possibly associated with delayed cancer diagnosis and increased cancer mortality.
Public health services, including cancer screening tests, have been affected by the onset of the COVID-19 epidemic.
To investigate the pandemic’s association with cancer screening worldwide.
In this systematic review and meta-analysis, databases such as PubMed, ProQuest, and Scopus were searched comprehensively for articles published between January 1, 2020, and December 12, 2021.
Observational studies and articles that reported data from cancer registries that compared the number of screening tests performed before and during the pandemic for breast, cervical, and colorectal cancer were included.
Data Extraction and Synthesis
Two pairs of independent reviewers extracted data from the selected studies. The weighted average of the percentage variation was calculated between the 2 periods to assess the change in the number of cancer screening tests performed during the pandemic. Stratified analysis was performed by geographic area, period, and type of setting. The systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.
Main Outcomes and Measures
The main outcome was the weighted average percentage variation in the number of screening tests performed between January and October 2020 compared with the previous period.
The review comprised 39 publications. There was an overall decrease of −46.7% (95% CI, −55.5% to −37.8%) for breast cancer screening, −44.9% (95% CI, −53.8% to −36.1%) for colorectal cancer screening, and −51.8% (95% CI, −64.7% to −38.9%) for cervical cancer screening during the pandemic. For all 3 cancers, a U-shaped temporal trend was identified; for colorectal cancer, a significant decrease was still apparent after May 2020 (in June to October, the decrease was −23.4% [95% CI, −44.4% to −2.4%]). Differences by geographic area and screening setting were also identified.
Conclusions and Relevance
A summary estimate of the downscaling of cancer screening tests since the onset of the COVID-19 pandemic is provided in this systematic review and meta-analysis. This could be associated with an increase in the number of avoidable cancer deaths. Effective interventions are required to restore the capacity of screening services to the prepandemic level.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: May 18, 2022.
Published Online: July 7, 2022. doi:10.1001/jamaoncol.2022.2617
Corresponding Author: Paolo Boffetta, MD, Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy (email@example.com).
Author Contributions: Drs Teglia and Angelini had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Teglia, Angelini, Boffetta.
Acquisition, analysis, or interpretation of data: Teglia, Angelini, Astolfi, Casolari.
Drafting of the manuscript: Teglia, Angelini, Astolfi, Casolari.
Critical revision of the manuscript for important intellectual content: Teglia, Angelini, Boffetta.
Statistical analysis: Teglia, Angelini.
Supervision: Teglia, Angelini, Boffetta.
Conflict of Interest Disclosures: None reported.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.